FindTrial
Sign In

CLINICAL STUDY COMPARING ADJUVANT THERAPY WITH CLODRONATE VERSUS PLACEBO IN PATIENTS WITH CANCER OF MAMA TEMPARNA WHO RECEIVE SYSTEMIC CHEMOTHERAPY AND / OR TAMOXIFEN OR NON-THERAPY

CLINICAL STUDY COMPARING ADJUVANT THERAPY WITH CLODRONATE VERSUS PLACEBO IN PATIENTS WITH CANCER OF MAMA TEMPARNA WHO RECEIVE SYSTEMIC CHEMOTHERAPY AND / OR TAMOXIFEN OR NON-THERAPY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-102-03
Enrollment
Unknown
Registered
2004-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

clodronate Type of group
Clodronate will be administered 1600 mg / day for 3 years Group name:Placebo Type of group
Clodronate placebo will be administered 1600 mg / day for 3 years.

Sponsors

EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients will be stratified according to age, state of the lymph nodes and status of the estrogen and progesterone receptors. Patients should not have evidence of meiastatic disease.

Exclusion criteria

Exclusion criteria: not contemplated

Design outcomes

Primary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Secondary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Countries

Peru, United States

Outcome results

None listed

Source: REPEC (via WHO ICTRP)